Evis X1
Evis X1 has been studied in 1 paper since 2025: 1 observational study in people; 1 in the past year. The newest paper, Dec 19, 2025: “Comparison of adenoma detection rate using the novel 5-LED vs xenon-light endoscopic system: Propensity score matching analysis”.
1 paper studies it2 findingsUpdated
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“ADR was slightly higher in the X1 group (36.1%) than the LUCERA group (32.1%), although not statistically significant ( P = 0.147).”
None of its findings points the other way.
- 1 lab in 1 country
- Humans1
What did studies of evis X1 find?
2Studies of evis X1 measured 2 outcomes: adenomas per colonoscopy and adenoma detection rate.
Adenomas per colonoscopy
upin humans1
1 study
Adenomas per colonoscopy
upin humans1
Evis X1 is linked with higher adenomas per colonoscopy in humans (Compared with EVIS LUCERA ELITE after propensity score matching) (0.77 versus 0.61; P = 0.034).
“APC (0.77 vs. 0.61, P = 0.034) and PPC (0.95 vs. 0.75, P = 0.023) were significantly higher with X1.”
HumansCompared with EVIS LUCERA ELITE after propensity score matchingn = 660
Endoscopy international open
Adenoma detection rate
no changein humans1
1 study
Adenoma detection rate
no changein humans1
Evis X1 was not clearly linked with adenoma detection rate in humans (Compared with EVIS LUCERA ELITE after propensity score matching) (36.1% versus 32.1%; P = 0.147).
“ADR was slightly higher in the X1 group (36.1%) than the LUCERA group (32.1%), although not statistically significant ( P = 0.147).”
HumansCompared with EVIS LUCERA ELITE after propensity score matchingn = 660
Endoscopy international open